开发治疗多重耐药鲍曼不动杆菌引起感染的新治疗方法：鲍曼不动杆菌治疗学。
Developing new therapeutic approaches for treating infections caused by multi-drug resistant Acinetobacter baumannii: Acinetobacter baumannii therapeutics.
机构信息
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
出版信息
J Infect. 2020 Dec;81(6):857-861. doi: 10.1016/j.jinf.2020.10.016. Epub 2020 Oct 25.
Antimicrobial resistance (AMR) represents a major challenge to global health. This problem is most apparent in healthcare facilities, with a comparatively small number of pathogens being responsible for a substantial burden of hospital acquired infections globally. One of the key pathogens is the Gram-negative coccobacilli, Acinetobacter baumannii. It has been estimated that between 47% and 93% of A. baumannii infections are associated with multi-drug resistance (MDR), which is facilitated through a variety of well documented mechanisms (β-lactamases, efflux pumps, aminoglycoside-modifying enzymes, permeability defects, and target modifications). As our current pool of antimicrobial treatments becomes increasingly less effective, it is vital to identify new targets that can aid in the development novel treatments and strategies. In this we review we outline the key virulence mechanisms in A. baumannii (gene acquisition and adaptation, resistance to stresses, biofilm formation, and host interaction) and discuss their potential as targets for new therapeutics to reduce the impact of infections caused by MDR A. baumannii.
抗菌药物耐药性（AMR）对全球健康构成重大挑战。这个问题在医疗机构中最为明显，少数几种病原体导致了全球大量医院获得性感染。革兰氏阴性球杆菌鲍曼不动杆菌是关键病原体之一。据估计，47%至 93%的鲍曼不动杆菌感染与多药耐药性（MDR）有关，这是通过多种有充分记录的机制（β-内酰胺酶、外排泵、氨基糖苷修饰酶、通透性缺陷和靶位修饰）促成的。由于我们目前的抗菌药物治疗方法越来越无效，因此确定新的靶点以帮助开发新的治疗方法和策略至关重要。在这篇综述中，我们概述了鲍曼不动杆菌中的关键毒力机制（基因获得和适应、抵抗压力、生物膜形成和宿主相互作用），并讨论了它们作为新疗法靶点的潜力，以减少由 MDR 鲍曼不动杆菌引起的感染的影响。
Zotero 插件